Drug intelligence / Profile preview

LB101

Development stage: Discontinued
Lead developer: Centessa Pharmaceuticals
Modality: Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics
Administration: Intravenous

Overview

LB101 is a conditionally tetravalent PD-L1xCD47 bispecific monoclonal antibody developed by Centessa Pharmaceuticals. It targets solid tumors by inhibiting PD-L1 and CD47. The mechanism involves blocking CD47 domains by PD-L1 domains until they are activated in the tumor microenvironment, enhancing antibody-dependent cellular phagocytosis (ADCP) without systemic toxicity[1][3][6].

Other names: LB-101LB101LB 101LB1LB-1LB 1

Targets

CD274 (Programmed cell death protein 1 ligand 1)CD47 (Cluster of Differentiation 47)

Beyond the preview

Go deeper on LB101.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on LB101.

Explore the full profile